1172 related articles for article (PubMed ID: 30286416)
1. Repeat-dose ketamine augmentation for treatment-resistant depression with chronic suicidal ideation: A randomized, double blind, placebo controlled trial.
Ionescu DF; Bentley KH; Eikermann M; Taylor N; Akeju O; Swee MB; Pavone KJ; Petrie SR; Dording C; Mischoulon D; Alpert JE; Brown EN; Baer L; Nock MK; Fava M; Cusin C
J Affect Disord; 2019 Jan; 243():516-524. PubMed ID: 30286416
[TBL] [Abstract][Full Text] [Related]
2. Rapid and Sustained Reductions in Current Suicidal Ideation Following Repeated Doses of Intravenous Ketamine: Secondary Analysis of an Open-Label Study.
Ionescu DF; Swee MB; Pavone KJ; Taylor N; Akeju O; Baer L; Nyer M; Cassano P; Mischoulon D; Alpert JE; Brown EN; Nock MK; Fava M; Cusin C
J Clin Psychiatry; 2016 Jun; 77(6):e719-25. PubMed ID: 27232360
[TBL] [Abstract][Full Text] [Related]
3. A Randomized, Double-Blind, Midazolam-Controlled Trial of Low-Dose Ketamine Infusion in Patients With Treatment-Resistant Depression and Prominent Suicidal Ideation.
Su TP; Li CT; Lin WC; Wu HJ; Tsai SJ; Bai YM; Mao WC; Tu PC; Chen LF; Li WC; Chen MH
Int J Neuropsychopharmacol; 2023 May; 26(5):331-339. PubMed ID: 36966411
[TBL] [Abstract][Full Text] [Related]
4. Continuation phase intravenous ketamine in adults with treatment-resistant depression.
Vande Voort JL; Morgan RJ; Kung S; Rasmussen KG; Rico J; Palmer BA; Schak KM; Tye SJ; Ritter MJ; Frye MA; Bobo WV
J Affect Disord; 2016 Dec; 206():300-304. PubMed ID: 27656788
[TBL] [Abstract][Full Text] [Related]
5. The effect of single administration of intravenous ketamine augmentation on suicidal ideation in treatment-resistant unipolar depression: Results from a randomized double-blind study.
Feeney A; Hock RS; Freeman MP; Flynn M; Hoeppner B; Iosifescu DV; Trivedi MH; Sanacora G; Mathew SJ; Debattista C; Ionescu DF; Fava M; Papakostas GI
Eur Neuropsychopharmacol; 2021 Aug; 49():122-132. PubMed ID: 34090255
[TBL] [Abstract][Full Text] [Related]
6. Single i.v. ketamine augmentation of newly initiated escitalopram for major depression: results from a randomized, placebo-controlled 4-week study.
Hu YD; Xiang YT; Fang JX; Zu S; Sha S; Shi H; Ungvari GS; Correll CU; Chiu HF; Xue Y; Tian TF; Wu AS; Ma X; Wang G
Psychol Med; 2016 Feb; 46(3):623-35. PubMed ID: 26478208
[TBL] [Abstract][Full Text] [Related]
7. Rapid and sustained antidepressant effects of intravenous ketamine in treatment-resistant major depressive disorder and suicidal ideation: a randomized clinical trial.
Zolghadriha A; Anjomshoaa A; Jamshidi MR; Taherkhani F
BMC Psychiatry; 2024 May; 24(1):341. PubMed ID: 38714931
[TBL] [Abstract][Full Text] [Related]
8. Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder.
DiazGranados N; Ibrahim LA; Brutsche NE; Ameli R; Henter ID; Luckenbaugh DA; Machado-Vieira R; Zarate CA
J Clin Psychiatry; 2010 Dec; 71(12):1605-11. PubMed ID: 20673547
[TBL] [Abstract][Full Text] [Related]
9. Antidepressant and antisuicidal effects of ketamine on the functional connectivity of prefrontal cortex-related circuits in treatment-resistant depression: A double-blind, placebo-controlled, randomized, longitudinal resting fMRI study.
Chen MH; Lin WC; Tu PC; Li CT; Bai YM; Tsai SJ; Su TP
J Affect Disord; 2019 Dec; 259():15-20. PubMed ID: 31437695
[TBL] [Abstract][Full Text] [Related]
10. Ketamine for acute suicidal ideation. An emergency department intervention: A randomized, double-blind, placebo-controlled, proof-of-concept trial.
Domany Y; Shelton RC; McCullumsmith CB
Depress Anxiety; 2020 Mar; 37(3):224-233. PubMed ID: 31733088
[TBL] [Abstract][Full Text] [Related]
11. Maintenance of antidepressant and antisuicidal effects by D-cycloserine among patients with treatment-resistant depression who responded to low-dose ketamine infusion: a double-blind randomized placebo-control study.
Chen MH; Cheng CM; Gueorguieva R; Lin WC; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Krystal JH; Su TP
Neuropsychopharmacology; 2019 Nov; 44(12):2112-2118. PubMed ID: 31421635
[TBL] [Abstract][Full Text] [Related]
12. Antisuicidal effect, BDNF Val66Met polymorphism, and low-dose ketamine infusion: Reanalysis of adjunctive ketamine study of Taiwanese patients with treatment-resistant depression (AKSTP-TRD).
Chen MH; Lin WC; Wu HJ; Cheng CM; Li CT; Hong CJ; Tu PC; Bai YM; Tsai SJ; Su TP
J Affect Disord; 2019 May; 251():162-169. PubMed ID: 30925267
[TBL] [Abstract][Full Text] [Related]
13. Neurocognitive effects of ketamine and association with antidepressant response in individuals with treatment-resistant depression: a randomized controlled trial.
Murrough JW; Burdick KE; Levitch CF; Perez AM; Brallier JW; Chang LC; Foulkes A; Charney DS; Mathew SJ; Iosifescu DV
Neuropsychopharmacology; 2015 Mar; 40(5):1084-90. PubMed ID: 25374095
[TBL] [Abstract][Full Text] [Related]
14. Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD).
Fava M; Freeman MP; Flynn M; Judge H; Hoeppner BB; Cusin C; Ionescu DF; Mathew SJ; Chang LC; Iosifescu DV; Murrough J; Debattista C; Schatzberg AF; Trivedi MH; Jha MK; Sanacora G; Wilkinson ST; Papakostas GI
Mol Psychiatry; 2020 Jul; 25(7):1592-1603. PubMed ID: 30283029
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and Safety of a Rapid Intravenous Injection of Ketamine 0.5 mg/kg in Treatment-Resistant Major Depression: An Open 4-Week Longitudinal Study.
Vidal S; Gex-Fabry M; Bancila V; Michalopoulos G; Warrot D; Jermann F; Dayer A; Sterpenich V; Schwartz S; Vutskits L; Khan N; Aubry JM; Kosel M
J Clin Psychopharmacol; 2018 Dec; 38(6):590-597. PubMed ID: 30346333
[TBL] [Abstract][Full Text] [Related]
16. Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I).
Fu DJ; Ionescu DF; Li X; Lane R; Lim P; Sanacora G; Hough D; Manji H; Drevets WC; Canuso CM
J Clin Psychiatry; 2020 May; 81(3):. PubMed ID: 32412700
[TBL] [Abstract][Full Text] [Related]
17. Commentary on Cochrane review: "Ketamine and other glutamate receptor modulators for depression in adults with unipolar major depressive disorder".
Borentain S; Desai P; Fu DJ; Nancy Chen L; Lane R; Mathews M; Canuso CM
J Psychopharmacol; 2023 Aug; 37(8):836-844. PubMed ID: 36218274
[TBL] [Abstract][Full Text] [Related]
18. Antidepressant and anti-suicidal effects of ketamine in treatment-resistant depression associated with psychiatric and personality comorbidities: A double-blind randomized trial.
Ahmed GK; Elserogy YM; Elfadl GMA; Ghada Abdelsalam K; Ali MA
J Affect Disord; 2023 Mar; 325():127-134. PubMed ID: 36623562
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
Daly EJ; Singh JB; Fedgchin M; Cooper K; Lim P; Shelton RC; Thase ME; Winokur A; Van Nueten L; Manji H; Drevets WC
JAMA Psychiatry; 2018 Feb; 75(2):139-148. PubMed ID: 29282469
[TBL] [Abstract][Full Text] [Related]
20. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant.
Ballard ED; Luckenbaugh DA; Richards EM; Walls TL; Brutsché NE; Ameli R; Niciu MJ; Vande Voort JL; Zarate CA
J Psychiatr Res; 2015 Sep; 68():68-73. PubMed ID: 26228403
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
